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The liver is an organ with strong regenerative capacity, yet primary hepatocytes have a low amplification potential 
in vitro, a major limitation for the cell-based therapy of liver disorders and for ex vivo biological screens. Induced 
pluripotent stem cells (iPSCs) may help to circumvent this obstacle but often harbor genetic and epigenetic abnor-
malities, limiting their potential. Here, we describe the pharmacological induction of proliferative human hepatic 
progenitor cells (HPCs) through a cocktail of growth factors and small molecules mimicking the signaling events 
involved in liver regeneration. Human HPCs from healthy donors and pediatric patients proliferated vigorously 
while maintaining their genomic stability and could be redifferentiated in vitro into metabolically competent cells 
that supported the replication of hepatitis B and delta viruses. Redifferentiation efficiency was boosted by three-di-
mensional culture. Finally, transcriptome analysis showed that HPCs were more closely related to mature hepato-
cytes than iPSC-derived hepatocyte-like cells were. Conclusion: HPC induction holds promise for a variety of 
applications such as ex vivo disease modeling, personalized drug testing or metabolic studies, and development of a 
bioartificial liver. (Hepatology 2019;0:1-18).
The liver has a unique regenerative capacity, with both parenchymal and nonparenchymal cells contributing to this process.(1,2) Upon 
liver injury, hepatic cells can morph into partially 
dedifferentiated progenitors, which yield hepato-
cytes and bile duct epithelial cells that can restore 
the organ’s original size and normal function.(3) 
Nevertheless, primary human hepatocytes (PHHs) 
do not spontaneously divide in vitro.(4) This is an 
important limitation for ex vivo disease modeling and 
cell-based therapy, an attractive alternative to liver 
transplantation, which can be curative for a number 
of inherited and acquired hepatic diseases but is ham-
pered by the shortage of donors.(3)
Cell fate can be dramatically altered by the over-
expression of transcription factors. Examples range 
from the reprogramming of a wide spectrum of adult 
cells into induced pluripotent stem cells (iPSCs) to 
direct trans-differentiation of fibroblasts to hepato-
cytes, circumventing the pluripotent state.(5-7) iPSCs 
are endowed with intrinsic self-renewal ability and 
the potential to differentiate into any of the three 
germ layers, allowing them to produce large amounts 
of gene-corrected transplantable hepatocytes for the 
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treatment of congenital liver diseases.(8) However, 
the generation of iPSCs is limited by the occurrence 
of epigenetic abnormalities and chromosomal rear-
rangements,(9,10) which notably result in the improper 
resetting of transposable element (TE) control.(11)
The successful growth of human primary bipo-
tent biliary cells in three-dimensional (3D) organ-
oids(12) and expansion of adult-derived human liver 
mesenchyme-like cells(13) indicate that some human 
liver cells can be amplified ex vivo. Hepatocytes 
were not considered good candidates for this type of 
manipulation due to their quiescence in the absence 
of liver damage,(14) but recent studies have demon-
strated that their proliferation can be induced in 
vitro, albeit to a modest extent.(15)
Collectively, these studies highlight the impor-
tance of cell signaling for directing cell fate, and 
developmental genes such as Wnt,(16) Notch,(17) 
and fibroblast growth factor 2 (Fgf2)(18) have been 
demonstrated to play major regulatory roles in 
mouse liver progenitor cells.(14) Perivenous hepato-
cytes also respond to Wnt signaling upon liver 
damage.(2) Furthermore, the Wnt and FGF path-
ways synergize to promote hepatoblast proliferation 
during growth of the liver bud,(19) allowing hepatic 
specification.(20) Wnt and β-FGF signaling are also 
induced during the proliferative phase of mouse 
liver regeneration together with epidermal growth 
factor (EGF), among others.(21)
Based on this premise, we developed a method 
for generating proliferative hepatic progenitor cells 
(HPCs) by ex vivo exposure of human primary liver 
cells to a cocktail of growth factors and small mole-
cules mimicking Wnt, EGF, and FGF signaling. This 
protocol resulted in the efficient reprogramming of 
PHHs into precursor cells that could be expanded 
more than 100,000 times in culture and could be dif-
ferentiated in vitro into metabolically competent cells 
that supported the replication of hepatitis B virus 
(HBV) and hepatitis delta virus (HDV).
Materials and Methods
Cell CUltURe
PHHs from pediatric patients were isolated by three-
step liver perfusion.(22) Liver lobes were obtained from 
children undergoing liver transplantation for inborn met-
abolic liver disease in the Swiss Center for Liver Diseases 
at the University Hospitals of Geneva (parents’ written 
consent and approval from the Canton of Geneva ethics 
committee: protocol number 08-028). PHHs from adult 
healthy donors were purchased from Biopredic (France). 
Briefly, 2 × 105 PHHs from all donors were plated on 
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collagen type I (Gibco)–coated wells and maintained in 
Hepatocyte Basal Medium (HBM Bullet kit; Lonza).
HpCS
HPCs from 5 pediatric patients (1 healthy donor 
and 4 different inborn metabolic liver diseases) and 
4 adult healthy donors were generated by cultur-
ing PHHs in Dulbecco’s modified Eagle’s medium 
(DMEM)-F12 Ham 15 mM 4-(2-hydroxyethyl)- 
1-piperazine  ethanesulfonic acid (HEPES) with 
Na-bicarbonate (Sigma), 1% glutamine, 1% penicillin/ 
streptomycin, 1% NEAA, 10% Knockout-Serum 
replacer (Gibco), 5% fetal bovine serum (FBS), 10 ng/mL 
EGF (Peprotech), 10 ng/mL basic FGF (R&D), and 
3 μM CHIR99021 (Sigma). Cells were cultured on 
collagen I–coated plates and passaged weekly 1/6 with 
StemPro accutase (Gibco). Cell quantification was per-
formed using the Countess Automated Cell Counter 
(Thermo-Fisher) during cell expansion of 5 different 
donors (Crigler-Najjar type 1 [CNI], citrullinemia 
[CIT], complement factor H deficiency, healthy 
donors 1 and 2). Hepatocyte dedifferentiation was 
performed more than 3 times for several samples. For 
cryopreservation, cells were frozen in DMEM-F12 
Ham 15 mM HEPES 10% Knockout-Serum replacer, 
5% FBS, and 10% dimethylsulfoxide (DMSO).
IpSC geNeRatIoN
Lentiviral (LV) particles encoding octamer 4, 
Kruppel-like factor 4, SRY (sex-determining region 
Y)-box 2, and c-Myc (OKSM) were prepared as 
described.(22) PHHs (5 × 105) were plated on Matrigel 
or collagen before being transduced with LV-OKSM 
at a multiplicity of infection (MOI) of 20. After 5 days, 
cells were switched to mTeSR1 medium (Stemcell 
Technologies) and grown until reprogrammed colo-
nies emerged (~20 days). Human iPSC clones were 
picked and expanded on Matrigel-coated plates in 
mTeSR1 medium. iPSC characterization is described 
in the Supporting Information.
pRolIFeRatIoN aND ploIDy 
aSSayS
For ploidy studies, PHHs and HPCs were incubated 
with 15 μg/mL Hoechst 33342 (Invitrogen) together 
with 5 μM reserpine (Sigma) for 30 minutes at 37°C. 
A carboxyfluorescein succinimidyl ester (CFSE) uptake 
assay was performed following the manufacturer’s pro-
tocol (CellTrace CFSE Cell Proliferation Kit; Thermo-
Fisher). PHHs and passage-2 HPCs were harvested, 
incubated for 20 minutes at 37°C with CFSE staining 
solution, rinsed, and analyzed by flow cytometry.
aNtIBoDIeS aND FloW 
CytoMetRy
Supporting Table S3 details antibodies used for 
flow cytometry and immunofluorescence. Intracellular 
staining was done with the Cytofix/Cytoperm kit 
(BD). Cells were either acquired on a Gallios or 
sorted using a FACSAria-II (BD) and analyzed using 
FlowJo (Tree Star) software.
RNa ISolatIoN aND 
SeQUeNCINg aND MRNa 
eXpReSSIoN
Total RNA was extracted with TRIzol Reagent (Life 
Technologies), purified using the PureLink RNA mini 
kit (Ambion), and treated with RNase-Free DNase 
(Qiagen) with an on-column DNase treatment. For 
mRNA sequencing, 100-bp single-end RNA-sequencing 
(RNA-seq) libraries were prepared using the Illumina 
TruSeq Stranded mRNA and the Illumina TruSeq SR 
Cluster Kit v4 reagents (Illumina). Sequencing was per-
formed with Illumina HiSeq 2500 in a 100-bp reads 
run. RNA-seq data are available in the Gene Expression 
Omnibus (GSE87560). Detailed bioinformatic anal-
yses are in the Supporting Information. mRNA was 
converted into complementary DNA (cDNA) using 
the SuperScript II reverse transcriptase kit (Invitrogen). 
Quantitative real-time PCR was performed using SYBR 
green supermix (Applied Biosystems). Fold change 
mRNA expression values were obtained by calculation 
of the double delta Ct versus two housekeeping genes, 
transferrin receptor and beta-2-microglobulin. Primer 
sequences are in Supporting Table S4.
pRoteIN eXpReSSIoN aND 
CytoCHRoMe p450 aCtIVIty
Albumin (ALB) secretion was measured in the cul-
ture medium by an enzyme-linked immunosorbent 
assay (ELISA) kit for human ALB (ICL) according 
to the manufacturer’s instructions. Cytochrome P450 
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(CYP) activity was detected by luminescence using 
the P450-Glo CYP3A4, CYP2C9, CYP1A2, and 
CYP2B6 kits (Promega).
HepatoSpHeRe geNeRatIoN 
aND CoNFoCal MICRoSCopy
Polyethylene glycol (PEG)–based, U-shaped 
microwell arrays were generated as described in the 
Supporting Information. HPCs and PHHs were 
seeded on each substrate to reach 1,200 cells per 
microwell. PHHs were mixed on ice with HPC 
transduced with LV-transthyretin (ttr).green fluo-
rescent protein (GFP) 1:4 together with 5 mg/mL 
collagen type I (Gibco) with a final seeding volume 
of 50 μL. Hepatospheres were incubated at 37°C for 
1 hour to sediment into the microwells, and culture 
medium was added afterward. Fifteen days after cul-
ture, hepatospheres were fixed with 4% paraformal-
dehyde, harvested, and spun in slides for staining. 
Immunofluorescence was performed as described in 
the Supporting Information. Confocal microscopy 
was performed with a Zeiss LSM700. Imaging was 
analyzed using Fiji/ImageJ.
HBV aND HDV paRtICleS aND 
aSSayS
Huh7–Na+–taurocholate cotransporting polypep-
tide (NTCP) cells, PHHs, and redifferentiated HPCs 
were seeded in 48-well plates and infected at an 
MOI of 1, 10, and 50 genome equivalents of HBV or 
HDV per cell. After 16 hours, media were collected 
and infected cells cultured in 2% DMSO primary 
hepatocyte maintenance medium to slow cell growth. 
HBV infection was assessed 10 days later by quan-
titative real-time PCR, whereas HDV infection was 
assessed 7 days later by quantitative real-time PCR. 
Production and infection of HBV and HDV particles 
are described in the Supporting Information.
MoUSe StRaINS aND Cell 
tRaNSplaNtatIoN
Experimental protocols were performed according 
to European Council guidelines and the Swiss Federal 
Veterinary Office on approval of the protocol by 
the Ethics Committee for Animal Care of the Vaud 
Region in Switzerland (license VD2865). For HPC 
transplantation, ten 12-week-old male nonobese dia-
betic (NOD)-Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) 
mice were pretreated with retrorsine (70 mg/kg intra-
peritoneally 4 and 2 weeks before transplantation). 
Two-thirds partial hepatectomy was performed prior 
to transplantation to induce cell engraftment. HPCs 
were injected intrahepatically in the remaining caudal 
lobe in two separated injections of 5 × 105 cells/40 
μL DMEM (five mice per HPC group), and three 
animals were injected with phosphate-buffered saline 
(PBS). Animals were sacrificed 7 days after transplan-
tation by pentobarbital injection, and livers were per-
fused with PBS to remove the blood for imaging. FRG 
(fumarylacetoacetate hydrolase [Fah–/–] recombination 
activating 2 [Rag2–/–] interleukin 2 receptor subunit 
gamma [Il2rg–/–]) mice (NOD background) were 
housed in the Plateau de Biologie Expérimentale de 
la Souris (Lyon, France). Experiments were performed 
in accordance with European Union guidelines on 
approval of the protocols by the local ethics committee 
(Authorization Agreement C2EA-15: CECCAPP, 
Lyon, France). PHHs and HPCs were injected intra-
splenically. Serum was harvested and stored at –80°C 
in aliquots. Human serum albumin (HSA) was quan-
tified by a Cobas C501 analyzer (Roche).
Results
IN VITRO geNeRatIoN oF 
pRolIFeRatIVe HpCS
Reasoning that it might not be necessary to repro-
gram hepatocytes all the way to iPSCs for ex vivo 
liver studies, we asked if inducing the signaling events 
that underlie the proliferative phase of liver regener-
ation and the embryonic development of the hepatic 
bud would trigger the dedifferentiation of human 
hepatocytes into ex vivo expandable progenitors. For 
this, we screened the potential of a series of growth 
factors and small molecules, alone or in combination 
(Supporting Table S1), to induce the proliferation of 
PHHs. Cells from 8 individuals, including 4 pediat-
ric patients undergoing transplantation for inherited 
metabolic disorders (Table 1), were tested. PHHs 
from all donors displayed the expression of classic 
hepatic markers alpha-1-antitrypsin (A1AT), hepato-
cyte nuclear factor 4A (HNF4A), CYP3A4, and ALB 
in culture (Supporting Table S2 and Fig. S1a). The 
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most promising cocktail contained 3 μM of the glyco-
gen synthase kinase-3 inhibitor CHIR99021, which 
activates Wnt signaling and is also used for chemical 
cell reprogramming,(23) together with 10 nm β-FGF 
and 10 nm EGF, previously found to induce hepato-
cyte division(24) (Fig. 1A).
Upon subjecting PHHs to the CHIR99021/
EGF/β-FGF cocktail, a stable population of highly 
proliferative cells was obtained in less than 7 days 
from all donors (Fig. 1A and Table 1). Proliferation 
of passage-2 HPCs (day 14) was assessed by CFSE 
uptake (Supporting Fig. S1b). Fluorescence inten-
sity was 10 times higher compared to PHHs, and 
fluorescent peaks corresponding to each cell division 
were clearly detected in HPCs but not in PHHs. 
Accordingly, >90% of passage-2 HPCs expressed 
the proliferation marker Ki67 by flow cytometry, 
whereas only 1% of PHHs did (Supporting Fig. S1c). 
Consistently with the activation of Wnt signal-
ing by CHIR99021, HPCs displayed increased 
expression of their transcriptional target Axin2(2) 
(Supporting Fig. S1d). Flow cytometry revealed two 
different PHH subpopulations based on cell size 
and complexity (Fig. 1B). DNA Hoechst staining 
further identified one population as diploid (2n) 
and the other as tetraploid (4n) or octoploid (8n) 
(Fig. 1B). All of these cells were negative for the 
definitive endoderm marker chemokine (C-X-C 
motif ) receptor 4 (CXCR4) and the proliferation 
marker Ki67 (Fig. 1D; Supporting Table S2). Upon 
dedifferentiation, 2n hepatocytes became positive 
for both CXCR4 and Ki67, whereas 4n and 8n 
cells also divided but remained negative for CXCR4 
(Fig. 1D). After several passages, we detected a 
high enrichment in 2n cells, with 4n and 8n cells 
still present but at a lower ratio (Fig. 1E). Under 
these conditions cell expansion was exponential 
through 8 weeks, one passage per week, result-
ing in up to 104-5 times the initial number of cells 
and after which a plateau was reached (Fig. 1F). 
Quantitative real-time PCR of CXCR4, Ki67, and 
the senescence marker p21/cyclin-dependent kinase 
inhibitor 1A across passages was performed in the 
cells to tackle the limited expansion (Supporting 
Fig. S1e). CXCR4 mRNA expression was signifi-
cantly higher in passage-2 HPCs compared to PHHs 
and then dropped by passage 5 (day 37). Ki67 levels 
rose highly at the beginning of the induction, cor-
roborating cell growth; but this marker was no longer 
detected from passage 5 on. Finally, p21 expression 
steadily increased with passages to display a marked 
difference with the starting population by passage 
5 (Supporting Fig. S1e). Expression of these mark-
ers was also analyzed across donor ages at passage 
2 as a representative time point of the exponential 
growth (Supporting Fig. S1f ). Induction of mRNA 
expression of CXCR4, Ki67, and p21 was detected 
in HPCs from the majority of donors compared to 
the PHHs of origin with variability among them. 
Interestingly, HPCs from the eldest donor (67 years 
old) presented lower mRNA levels of CXCR4 and 
Ki67 and higher p21 levels compared to cells from 
younger donors (Supporting Fig. S1f ).
MaRKeRS oF pRolIFeRatINg 
HepatoCyte-DeRIVeD CellS
Immunofluorescence staining revealed that expres-
sion of the mature hepatocyte markers ALB and 
HNF4α was lost during the first week of  culture, 
whereas that of A1AT was maintained (Fig. 2A; 
Supporting Table S2). Coexpression of keratin 7 
(KRT7) and hepatic markers has been described 
in liver progenitors undergoing epithelial- 
to- mesenchymal transition.(25) Accordingly, HPCs 
expressed the hepatic progenitor marker alpha- 
fetoprotein (AFP) together with KRT7 (Fig. 2A, top) 
and the mesenchymal stem cell markers cluster of dif-
ferentiation 73 (CD73), CD90, CD105, and CD44, 
detected by flow cytometry (Fig. 2B,C). Interestingly, 
we found differential expression of CD44, with higher 
average levels of this marker in 4n/8n than in 2n cells 
(Fig. 2B). PHHs did not express CD31 (endothelial 
taBle 1. Human primary Hepatocytes and Donor 
Information
Donor Disease Abbreviation Gender Age
1 Crigler-Najjar type 1 CNI Female 5
2 Citrullinemia CIT Male 1
3 Ornithine transcar-
bamylase 
deficiency
OTC Male 15
4 Complement factor 
H deficiency
CFH Female 11
5 Healthy donor 1 D1 Male 13
6 Healthy donor 2 D2 Female 26
7 Healthy donor 3 D3 Female 43
8 Healthy donor 4 D4 Male 67
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cell marker), leucine-rich repeat-containing G pro-
tein–coupled receptor 5 (LGR5, a bipotent biliary 
cell marker), and CD34 (hematopoietic cell marker) 
(Fig. 2D; Supporting Table S2). Whereas CD34 and 
LGR5 were also absent in HPCs, low levels of CD31 
were detected in this population (Fig. 2E).
The redifferentiation potential of CNI-HPCs was 
assessed in two dimensions (2D) by switching the 
CHIR99021/EGF/FGF2-containing medium to 
hepatocyte basal medium supplemented with a stan-
dard hepatocyte differentiation cocktail(8) of 20 ng/mL 
oncostatin M and 1 µM dexamethasone for 7 days. 
Under these conditions, the cells recovered the typical 
hexagonal shape of PHHs and up-regulated mature 
hepatocyte markers such as HNF4α and CYP3A4, 
undetectable in HPCs (Supporting Fig. S2a). They also 
significantly up-regulated mRNA levels of ALB, A1AT, 
and HNF4α by day 7, whereas the levels of endoder-
mal and hepatoblast markers AFP, CXCR4, and KRT 
decreased (Supporting Fig. S2b). The redifferentia-
tion ability of HPCs was compared to that of iPSCs 
generated from the same donor, using CNI-PHHs 
(Supporting Fig. S3a-c). CNI-iPSCs were differentiated 
into hepatocyte-like cells (HLCs) following a described 
protocol.(8) Expression of markers from each differen-
tiation cell stage was analyzed by quantitative real-time 
PCR (Supporting Fig. S2c). In addition, HLC marker 
expression was confirmed by immunofluorescence 
(Supporting Fig. S2d). HPC-derived and iPSC- 
derived HLCs displayed similar levels of CYP3A4 
activity (Supporting Fig. S2e), indicative of their met-
abolic maturation. However, amounts of secreted ALB 
were lower in HPC-derived HLCs compared to PHHs 
and iPSC-derived HLCs (Supporting Fig. S2f ).
tRaNSCRIptoMeS oF 
HepatoCyte-DeRIVeD HpCS, 
IpSCS, aND DIFFeReNtIateD 
pRoDUCtS
We used transcriptome data to compare CNI-
PHHs and CIT-PHHs (Table 1), reprogramming into 
iPSCs to PHH dedifferentiation into HPCs and their 
redifferentiation into HLCs. A principal component 
analysis unveiled a clustering of the samples accord-
ing to their level of differentiation and the protocol 
used for hepatocyte reprograming (Fig. 3A). Samples 
obtained during the dedifferentiation and redifferen-
tiation of PHHs clustered together close to HPCs, in 
an area of the plot clearly distinct from that occupied 
by samples corresponding to the reprogramming of 
PHHs into iPSCs (Fig. 3A). A comparative analysis 
of the transcriptomes of these cells concentrating on 
the 5,000 protein-coding genes with the highest stan-
dard deviation across samples further revealed that the 
in vitro 2D redifferentiation of HPCs induced more 
hepatocyte-specific transcripts than were found in 
HLCs derived from iPSCs (Fig. 3B). In addition, a 
high number of pluripotency-specific transcripts were 
still present in these HLCs, although redifferentiated 
HPCs also displayed progenitor cell RNAs, indicat-
ing that neither protocol allowed for full recovery of a 
PHH molecular phenotype.
To extend these results, we performed a more 
detailed analysis of the expression of stage-specific 
transcripts throughout PHH dedifferentiation into 
HPCs, reprogramming into iPSCs and maturation of 
either product toward HLCs (Fig. 3C). As expected, 
transduction of hepatocytes with the OKSM lentiviral 
vector resulted in the expression of stem cell genes and 
silencing of their hepatospecific counterparts (Fig. 3C). 
It also induced up-regulation of the mesenchymal 
markers CD105, CD73, and CD90, with the latter 
alone still detectable in iPSCs. Kruppel-like factor 
4, CD133, and kinase insert domain receptor mark-
ers (Supporting Table S2) were induced during both 
PHH dedifferentiation and reprogramming, whereas 
POU class 5 homeobox 1 (OCT4), Nanog homeobox 
(NANOG), and SRY (sex-determining region Y)-box 
2 (SOX2) were exclusively induced during iPSC gen-
eration (Fig. 3C; Supporting Table S2). Expression of 
some endoderm-specific and hepatoblast-specific genes 
was maintained during hepatocyte dedifferentiation, as 
were some mature hepatocyte markers such as A1AT.
TEs account for over half of the human genome, 
and transcripts emanating from their sequences provide 
FIg. 1. Generation of induced HPCs from PHHs. (A) Experimental protocol and morphological changes in primary hepatocytes 
during the first week of induction and at 30 days. (B) DNA Hoechst 33342 staining of primary hepatocytes and sorting based on ploidy. 
(C) CXCR4 and Ki67 expression by f low cytometry of primary hepatocytes and (D) HPCs. (E) Ploidy representation in passage-2 
HPCs by DNA Hoechst staining. (F) Comparative rates of in vitro cell expansion of primary hepatocytes (average of 5 donors) in 
induction culture medium or hepatocyte culture medium. Abbreviations: FSC, forward scatter; SSC, side scatter.
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a high-density cellular barcode (which we coined the 
“transposcriptome”).(26) It has been observed that TEs 
are transiently deregulated and may not be reset prop-
erly during iPSC reprogramming.(11,27) The high degree 
of stage specificity of the transposcriptome underlined 
great differences between iPSC-derived HLCs and 
their source hepatocytes in the heatmap representation 
(Supporting Fig. S4a), which contrasted with much 
fewer differences between these primary cells and their 
HPC derivatives. Furthermore, transcript expression of 
specific TE families in PHHs versus iPSCs and HPCs 
(Supporting Fig. S4b,c) spotlighted the up-regulation 
of human endogenous retroviruses (HERVs) in the 
two latter. This was expected for iPSCs as HERV-H 
expression was previously noted to be essential for 
human embryonic stem cell (hESC) pluripotency(28) 
but unknown for hepatic progenitors. A Venn dia-
gram revealed that the majority of the up-regulated 
HERV-Hs in HPCs were the same transcripts that are 
expressed in iPSCs and hESCs (Supporting Fig. S4d).
geNoMIC StaBIlIty oF pHH-
DeRIVeD HpCS
In order to probe for the occurrence of DNA rear-
rangements during PHH dedifferentiation, we performed 
a copy number variation array analysis (Fig. 4A-C). No 
outstanding anomaly was detected upon CNI-PHH 
and CIT-PHH dedifferentiation across chromosomes 
(Fig. 4A,B). CNI-PHH reprogramming to iPSCs 
resulted in several copy number alterations, as described(10) 
(Fig. 4C, central panel, highlighted in green). Notably, 
there also was a major rearrangement within chromo-
some 20 of one iPSC clone, which had gone undetected 
by simple karyotype analysis and was maintained upon 
differentiation to HLCs (Fig. 4C, right panel).
HpC-DeRIVeD HepatoCyteS 
SUppoRt HBV aND HDV 
ReplICatIoN
Chronic HBV and HDV infections are major world-
wide causes of liver disease. The absence of robust cell 
culture models to study virus–host interactions has been 
hampering the search for curative treatments against 
these pathogens.(29) PHHs were long the gold stan-
dard for HBV studies because, in contrast to hepatoma 
cell lines, they do express the HBV and HDV entry 
receptor NTCP (solute carrier family 10 member 1 
[SLC10A1]).(30) RNA-seq data showed that HNF4 and 
the retinoid X nuclear receptor alpha (RXRA), which 
are essential cofactors for HBV replication,(31) were 
expressed in HPCs (Fig. 5A). In contrast, SLC10A1 
transcripts were not detected in these cells, but expres-
sion of the viral receptor was recovered upon their 
redifferentiation into HLCs (Fig. 5A). We thus asked 
if HPC-derived HLCs could support HBV and HDV 
entry and replication. For this, HPCs were cultured for 
5 days in the hepatocyte differentiation medium before 
exposure to HBV and HDV particles, with PHHs and 
NTCP-expressing Huh7 cells serving as positive con-
trols and native Huh7 cells as negative controls, respec-
tively. Nine days postinfection, viral genomes in cell 
lysates were quantified by quantitative real-time PCR. 
HBV and HDV genomes were detected in the HPC-
derived HLCs at levels comparable to those measured 
in PHHs at high MOI, indicating that they were fully 
permissive for the early replicative steps of both viruses 
(Fig. 5B,C). As expected, we could not detect infec-
tion of Huh7 cells (Fig. 5D). In order to determine 
differentiated HPC competence to produce viral par-
ticles, we transfected HPC-derived HLCs, PHHs, or 
NTCP-Huh7 cells with two plasmids, one providing 
the envelope glycoproteins of HBV (pT7HB2.7) and 
the second driving the expression of the HBV prege-
nomic RNA, inactivated for these glycoproteins (pCi-
HBenv-) or, alternatively, with only the second of these 
constructs as a negative control. Levels of HBV particle 
production in the supernatant were then measured and 
found to be comparable between the three cell types at 
day 6 and higher in HPCs when the supernatant was 
collected at day 9 (Fig. 5E). Furthermore, their superna-
tants were equally infectious when used to infect fresh 
Huh7-NTCP cells (Fig. 5F). Therefore, we conclude 
that HPC-derived HLCs support all steps of HBV 
replication as efficiently as PHHs.
FIg. 2. Marker-based characterization of HPCs. (A) Marker expression by immunofluorescence during hepatic progenitor induction. 
Nuclei are stained with 4′,6-diamidino-2-phenylindole (blue). Scale bar, 100 µm. Expression of indicated mesenchymal stem cell markers 
by flow cytometry in (B) primary hepatocytes and (C) passage-3 HPCs. 2n and >2n cell populations are depicted in orange and red, 
respectively. Endothelial cell (CD31), hematopoietic cell (CD34), and bipotent cholangiocyte (LGR5) markers in (D) primary hepatocytes 
and (E) HPCs.
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optIMIZeD EX VIVO 
DIFFeReNtIatIoN oF HpCS
The dual expression of endoderm and mesenchy-
mal markers in HPCs suggested that their differen-
tiation potential might be better than revealed by the 
2D culture protocol used in our first round of exper-
iments. We thus generated round-bottom microw-
ell arrays made of PEG hydrogels to aggregate and 
differentiate HPCs from two CNI and CIT donors 
over 14 days into more physiological, 3D spheres.(32) 
Because the composition of the extracellular matrix 
FIg. 3. Comparing the protein-coding transcriptome of HPCs and iPSCs and products differentiated therefrom. (A) Principal 
component analysis of protein-coding genes during dedifferentiation of hepatocytes (PHHs) to HPCs and their 2D redifferentiation 
(data set 1, circles) and reprogramming of PHHs to iPSCs and their differentiation into HLCs (data set 2, triangles). (B) Heatmap 
illustrating levels of 5,000 protein-coding transcripts with the highest standard deviation across samples from data set 1 (HPC 
generation and their 2D redifferentiation) and data set 2 (iPSC generation and their differentiation into HLCs). Samples from primary 
hepatocytes sequenced in data set 1 are labeled with circles. (c) Heatmap representation showing RNA-seq normalized counts of a 
selection of cell stage–specific genes during generation and redifferentiation of iPSCs (left) and HPCs (right). Abbreviations: MSC, 
mesenchymal stem cell; PC, principal component.
FIg. 4. DNA array showing mutations, amplifications, and deletions across chromosomes in dedifferentiation of (A) CIT primary 
hepatocytes and (B) CNI primary hepatocytes to HPCs. (C) DNA array showing mutations, amplifications, and deletions across 
chromosomes during CNI-PHH reprogramming to iPSCs and differentiation to HLCs. Probes across the chromosomes are shown 
as black dots. Green lines and red lines highlight amplified and deleted regions, respectively. The length of the line is proportional to 
the effect. The X chromosome is shown as completely deleted in CIT samples due to female DNA of reference. Abbreviation: HEP, 
hepatocyte.
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(ECM) has an important influence on the regulation 
of cell fate,(33) we cultured the spheres without ECM 
or collagen type-I (Fig. 6A). Besides, in order to mimic 
further the in vivo environment, we generated mixed 
hepatospheres with collagen including HPCs and pri-
mary hepatocytes in a 1:4 proportion (Fig. 6A). HPCs 
FIg. 5. Redifferentiated HPC support HBV and HDV infection. (A) Expression levels of the NTCP receptor (SLC10A1) and two 
HBV replication cofactors (HNF4A and RXRA) in CIT hepatocytes, HPCs, and redifferentiated HPCs by RNA-seq. (B) HBV 
infectivity at different MOIs as assessed in Huh7-NTCP cells, redifferentiated HPCs, and PHHs by intracellular HBV quantitative 
real-time PCR DNA quantification. (C) HDV infectivity at different MOIs assessed in Huh7-NTCP cells, redifferentiated HPCs, and 
PHHs by intracellular HDV quantitative real-time PCR RNA quantification. (D) HBV infectivity in Huh7 versus Huh-NTCP cells. 
Results from (B-D) were normalized with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels and are expressed as means 
± standard deviations relative to genome equivalents per milliliter recovered from cell lysates performed in duplicate. (E) Production 
of HBV particles by transfection of Huh-NTCP cells, PHHs, or HPCs with equal amounts of pT7HB2.7 and/or pCIHBenv(–), as 
described in Materials and Methods. HBV DNA particles were collected at days 6 and 9 posttransfection from culture media, extracted, 
and quantified by quantitative real-time PCR. Results are expressed as means ± standard deviations relative to genome equivalents per 
milliliter performed in duplicate. (F) Comparison of HBV infectivity in Huh-NTCP cells with particles produced in Huh-NTCP cells, 
PHHs, or HPCs. HBV infectivity was assessed by intracellular HBV quantitative real-time PCR DNA quantification. The results 
were normalized with GAPDH levels and are expressed as means ± standard deviations relative to genome equivalents per milliliter 
recovered from cell lysates performed in duplicate. *P < 0.05, **P < 0.01 by two-way analysis of variance comparison. Abbreviations: 
GE, genome equivalent; ns, nonsignificant.
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were able to aggregate without ECM, although the 
spheres were smaller and less compact than the mixed 
hepatospheres (Fig. 6B-D, left panel).
In order to address HPC maturation in 3D com-
pared to 2D, cells were transduced with a lentiviral 
vector encoding GFP under the control of the hepato-
specific TTR promoter. GFP expression arose within 
the first 5 days of culture in hepatocyte differentiation 
media, in all conditions (Fig. 6B-D, central panels).
Two weeks after differentiation, both HPC-only 
and HPC:PHH mixed hepatospheres exhibited high 
CYP3A4 and ALB RNA expression (Fig. 6C,D, right 
panels). To characterize HPC maturation further, cells 
from CNI and CIT donors were cultured in differ-
entiation media for 14 days, and ALB levels were 
measured by ELISA (Fig. 6E). As expected, ALB was 
more abundant in the supernatant of 3D-grown com-
pared to 2D-grown HLCs. Nevertheless, we observed 
important interdonor differences, with ALB concen-
tration in the CIT HPC-derived HLC medium 10 
times higher than in that of their CNI counterparts, 
in both 2D and 3D cultures (Fig. 6E). This parame-
ter did not differ in the source primary hepatocytes. 
In addition, we analyzed the metabolic activity of 
four key P450 cytochromes upon HPC maturation 
(Fig. 6F). ALB secretion was higher in 3D-cultured 
than in 2D-cultured cells, although in this case 
we did not detect interdonor differences. Levels of 
CYP2C9 and CYP1A2 activity were comparable in 
3D-differentiated HLCs and PHHs, whereas HLCs 
reached only 70% and 50% of PHH CYP2B6 and 
CYP3A4 enzymatic activity, respectively (Fig. 6F).
lIMIteD lIVeR RepopUlatIoN 
poteNtIal oF HpCS
In order to probe further the differentiation poten-
tial of HPCs, we first injected these cells, marked with 
a TTR-GFP-containing lentiviral vector, into the liver 
of immunodeficient NOD–severe combined immuno-
deficient (SCID)-γ chain (NSG) mice preconditioned 
by retrorsine treatment and partial hepatectomy. To 
obtain a detailed imaging of the engrafted cells, the 
injected lobe was harvested 1 week upon injection, 
fixed, and cleared of its lipids, yielding a nearly trans-
parent piece of tissue that facilitated the detection of 
GFP-positive cells (Fig. 7A; Supporting Video S1). 
Immunofluorescence staining of frozen sections of the 
injected liver confirmed the coexpression of GFP and 
the mature hepatocyte markers A1AT and CYP3A4 
(Fig. 7B). Next, we tested the long-term engraftment 
potential of HPCs in a chronic hepatic failure mouse 
model. Passage-3 (day 18) CNI-HPCs (5 × 105) were 
injected in the spleen of Fah–/–Rag2–/–Il2rg–/– (NOD-
FRG) mice, and HSA levels were measured weekly for 
9 weeks. In these conditions, we were able to detect 
human cells in the liver of two out of four animals 
by Fumaryl-acetoacetate hydrolase (FAH) staining 
(Fig. 7C), some of which were human ALB-positive 
cells (Fig. 7C, middle). Human AFP-positive cells 
were also detected in the successfully engrafted mice 
(Fig. 7D, right), indicating incomplete differentiation 
of some of the engrafted cells. Cell-associated FAH 
levels were globally lower in HPC-derived liver cells 
than in engrafted PHHs (Fig. 7D), and levels of HSA 
were markedly higher in the blood of PHH-injected 
compared with HPC-injected animals (Fig. 7E). At 
week 10 postinjection, human DNA was detected 
predominantly in the spleen rather than the liver of 
HPC-transplanted FRG mice, whereas the opposite 
pattern was documented in PHH-transplanted ani-
mals (Fig. 7F). Therefore, human HPCs were able to 
engraft and differentiate into mature hepatocytes after 
in vivo xenotransplantation in immunodeficient mice, 
but they displayed limited homing and expansion 
capabilities in this setting.
FIg. 6. In vitro 3D differentiation of HPCs. (A) Scheme of hepatosphere generation with and without ECM in PEG-based microwell 
arrays. HPCs cultured with primary hepatocytes were at a 1:4 ratio. LV-ttr-GFP transduced HPCs were also cultured alone or in 
combination with primary PHHs. Imaging of (B) HPC differentiation in 2D, (C) HPC differentiation in 3D without ECM, and (D) 
HPC differentiation with PHHs (proportion 1:4) in 3D and collagen type I. Left panel, bright-field image of cell culture. Central 
panel, GFP-HPC 7 days upon LV-ttr-GFP transduction. Right panel, CYP3A4 and ALB staining 14 days upon differentiation. 
Scale bar, 100 µm. (E) ALB concentration in culture medium during HPC differentiation in 2D and 3D from two different donors. 
Left, CIT-HPC differentiation. Right, CNI-HPC differentiation. (F) Metabolic activity from four different P450 cytochromes upon 
HPC redifferentiation from two different donors (CNI and CIT) in 2D and 3D. From left to right, CYP3A4, CYP2C9, CYP1A2, 
and CYP2B6 activities. Results are expressed as means ± standard deviations from two independent experiments. Nonsignificant 
differences between differentiated HLCs and PHHs were obtained by Mann-Whitney test. Abbreviation: RLU, relative light unit.
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Discussion
The liver has a strong regenerative capacity, but 
primary hepatocytes divide very little in vitro and 
cannot be efficiently expanded without some sort of 
reprogramming.(34) iPSCs hold promise as a source 
of HLCs, but current differentiation protocols are 
unsatisfying both quantitatively (only a fraction of 
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the iPSCs can be induced to mature) and qualita-
tively (iPSC-derived HLCs keep expressing some 
fetal markers).(35) Furthermore, the maintenance of 
epigenetic features from the cells of origin and the 
high incidence of epigenetic and genetic abnormali-
ties arising during reprogramming(9) represent consid-
erable limitations for the use of iPSC-derived HLCs 
in the clinic.
We thus explored alternative methods for the gen-
eration of large supplies of cells with a strong hepatic 
differentiation potential. Through the combined 
activation of Wnt, β-FGF, and EGF signaling, we 
obtained cells that displayed the features of hepatic 
progenitors, could be massively expanded in culture, 
were easily transduced with lentiviral vectors, could be 
redifferentiated into cells that exhibited much of the 
molecular and metabolic properties of PHHs, and fully 
supported the replication of both HBV and HDV.
Our protocol only relied on pharmacological treat-
ment, without any genetic manipulation. It thus in 
itself does not carry the risk of insertional mutagene-
sis, a legitimate fear with iPSCs generated with repro-
gramming factors expressed from integrating vectors. 
HPCs were readily obtained with hepatocytes from 8 
different donors (healthy and sick), with an efficiency 
of dedifferentiation that approached 90%, which 
sharply contrasts with the usually low frequency of 
reprogramming of somatic cells into iPSCs. In addi-
tion, HPCs did not display chromosomal anomalies 
easily detected in iPSCs derived from the same pri-
mary hepatocytes. Finally, the growth of HPCs was at 
all times strictly dependent on the presence of drugs 
in the culture medium, indicating that they did not 
undergo transformation.
It was noted that Wnt-responsive diploid Axin2+ 
hepatocytes located around central veins fuel the 
homeostatic renewal of the liver.(2) Here, enrichment 
in the 2n population over cells of higher ploidy was 
observed upon combined activation of Wnt, β-FGF, 
and EGF signaling. In addition, we found that HPC 
generation was more efficient in previously sorted 
diploid cells and decreased with the age of the donor, 
possibly due to a reduced fraction of 2n cells in older 
livers.(36) HPCs expressed both endodermal and mes-
enchymal markers in culture. Mesenchymal markers 
are induced by continuous Wnt signaling as part of 
the epithelial-to-mesenchymal transition that occurs 
upon liver injury,(37) and this feature was also observed 
during the reprogramming of hepatocytes to iPSCs, 
suggesting that it is an integral part of hepatocyte 
reprogramming.
Supporting our findings, the pharmacological con-
version of primary mouse and rat hepatocytes into 
bivalent progenitor cells was recently reported.(38) 
Importantly, this other protocol did not succeed in 
generating proliferative cells from human hepato-
cytes.(38) We could verify this limitation and con-
versely found that our reprogramming regimen was 
inefficient at inducing the long-term proliferation 
of murine hepatocytes (data not shown). These spe-
cies-specific differences in the reprogramming ability 
of human and mouse hepatocytes are so far unex-
plained. Furthermore, the rodent HPCs displayed 
signs of genomic instability, with emergence of aneu-
ploidy and chromosomal rearrangements suggesting 
cell transformation,(38) whereas these anomalies were 
conspicuously absent from our human HPCs.
Interestingly, our transcriptome analyses revealed 
that human HPCs were more closely related to 
mature hepatocytes than iPSC-derived HLCs were, 
at least through the in vitro differentiation protocols 
used here. These analyses provided as well a very pre-
cise transposcriptome profile for steps of both the 
dedifferentiation and reprogramming of hepatocytes, 
confirming the significant advantage of using a com-
bination of protein-coding transcriptome and trans-
poscriptome as a method for cell qualification.(26) 
Furthermore, the transcription in HPCs of more 
than 300 HERV-H loci also expressed in hESCs 
demonstrates that activation of this primate-restricted 
endogenous retrovirus is not limited to pluripotent 
stem cells as previously believed.(27,28)
FIg. 7. In vivo HPC redifferentiation. (A) Lipid-cleared mouse liver lobe and 3D imaging of GFP-positive ttr-GFP-transduced 
HPC 1 week posttransplantation. (B) Immunofluorescence-based codetection of GFP and human A1AT (top) and GFP and human 
CYP3A4 (bottom) in the liver of mice injected with LV-ttr-GFP-transduced HPCs 1 week posttransplantation. (C) Left, human 
FAH; middle, human ALB; and right, human AFP immunohistochemistries on liver sections of NFRG (NOD Fah–/–Rag2–/–Il2rg–/–) 
mice transplanted with HPCs (passage 3) 10 weeks posttransplantation. (D) Human FAH, ALB, and AFP immunohistochemistries 
on liver sections of NFRG mice transplanted with PHHs 10 weeks posttransplantation. (E) HSA levels in transplanted mice at 
sacrifice. (F) Human Alu fragment amplification in the liver of engrafted mice with HPCs 10 weeks after transplantation (top) and 
mix of different percentages of human and mouse DNA (bottom). Scale bars, 100 or 50 µm.
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The outcome of our 3D hepatosphere culture 
differentiation protocol is encouraging as it sug-
gests that HPCs could be used for hepatic disease 
modeling or personalized drug testing, as well as for 
manufacturing a bioartificial liver.(39) Moreover, cul-
ture of HPCs in the absence of ECM resulted in 
successful hepatosphere generation with enhanced 
expression of mature hepatic markers, ALB secre-
tion, and up-regulation of the metabolic activity of 
cytochromes highly relevant for pharmacological 
studies. The efficiency of HPC differentiation was 
increased from 50% to 80% when switching from 
a 2D to a 3D culture system, highlighting how 
supracellular organization can impact on cell fate. 
This result warrants further efforts toward improv-
ing the ex vivo manipulation of these cells through 
systematic microenvironmental perturbation,(40) for 
instance, by capitalizing on the observation that 
decellularized livers provide scaffolds that support 
engraftment and proliferation of fetal hepatic pro-
genitors.(41) Other strategies for achieving enhanced 
differentiation would be studying further combina-
tions of small molecules and growth factors involved 
in liver differentiation or using 3D cocultures of 
HPCs with other liver cell types alone or in combi-
nation with ECM to mimic the liver milieu.
Despite their robust ex vivo proliferation and differ-
entiation capacity, our HPCs displayed a limited ability 
to repopulate a mouse liver following intrasplenic injec-
tion. Even though early-passage human HPCs could 
differentiate into hepatocytes and could be detected for 
several weeks in vivo, expansion was modest. It could 
be linked to their dedifferentiated phenotype as simi-
lar limitations have been noted after transplantation of 
either human liver stem cells(42) or human iPSC-derived 
hepatocyte-like cells,(43) or it could be related to the 
limited expansion potential of HPCs. Transplantation 
of redifferentiated cells was attempted with no success, 
probably due to the sensitivity of differentiated cells to 
harvesting that caused a high cell death rate (data not 
shown). Our results contrast with the far more success-
ful repopulation of the liver of cDNA–urokinase plas-
minogen activator/SCID mice recently reported for rat 
HPCs, but the transformed-like phenotype of these 
other cells may have contributed to their high in vivo 
proliferation potential.(38)
Still, the amplification rates of our human 
HPCs would yield enough hepatocytes to perform 
patient-specific ex vivo modeling and drug or viral 
screenings because a minimal number of primary cells 
would be initially required. In that respect, the value of 
our HPCs and more mature derivatives for addressing 
interindividual differences in susceptibility to HBV/
HDV replication and response to antiviral therapies 
should be compared to that of other recently described 
systems, such as the micropatterned culture of 
PHHs(44) or iPSC-derived HLCs.(31) More generally, 
our method should facilitate the creation of biobanks 
of human hepatocytes or precursors from individuals 
with different metabolic diseases, ages, ethnicities, and 
genders, allowing for a personalized analysis of drug 
metabolic stability, liver toxicity, and drug clearance 
in these various subgroups. In sum, the present meth-
odology provides a very promising lead for precision 
medicine and for the treatment of liver disorders.
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